Health & Biotech
Check out the latest news, insights and unique analysis brought to you by Stockhead's team of business journalists and industry experts on Chimeric Therapeutics.
RELATED STOCKHEAD STORIES
News
ASX Small Caps Lunch Wrap: ASX claws back early losses after sluggish start
News
Top 10 at 11: Drug trial progress and coal success are today’s news
Health & Biotech
Health Check: Latest biotech quarterly results are as patchy as the curate’s egg
Health & Biotech
Health Check: Thirsty Chimeric goes to the well for funding top-up
Health & Biotech
Health Check: Cancer drug developer Chimeric heads to blood bank for better patient cells
Health & Biotech
ASX Health Stocks: Telix’s brain-cancer imaging agent Pixclara handed to FDA for review
Health & Biotech
ASX Health Stocks: Lift off for LTR Pharma’s ED therapy under TGA scheme
Investor Guides
Investor Guide: Health & Biotech FY2025 featuring Tim Boreham
Health & Biotech
ASX Health Stocks: Immutep gets positive FDA feedback for lung cancer therapy
Health & Biotech
ASX Health Stocks: Health app firm MedAdvisor guides the market to record year and maiden profit
News
Closing Bell: ASX rides high as gold, silver, copper, and iron ore surge; Nuix jumps 25pc
Health & Biotech
ASX Health Stocks: Memphasys’ Felix triumphs over traditional sperm-prepping methods for IVF
News
Rise and Shine: Everything you need to know before the ASX opens
News
Closing Bell: ASX phones in more gains as prices plunge in Beijing and records tumble in New York
News
ASX Small Caps Lunch Wrap: Whose eight-year world record dream has gone up in smoke this week?
Health & Biotech
ASX Health Stocks: Cochlear upgrades guidance, Chimeric up 12pc after commencing Phase 1B trial on leukaemia
News
